Boston Scientific’s (BSX) gross margin for 1Q17 came in at around 70.6% of its total sales, as compared to a 72.3% gross margin in 1Q16.
In a Reuters survey of 24 brokerage companies on May 5, 2017, about 79% of these analysts rated Boston Scientific as a “buy,” while 21% rated it as a “hold.”
Pfizer (PFE) reported a 2% decline in revenues to $12.78 billion in 1Q17, compared to $13.00 billion in 1Q16.
To strengthen the innovative health business, the company is focusing on the development of new drugs as well as expanding the market reach of existing products.
Apart from Pfizer’s (PFE) product developments, let’s take a look at a few of the recent pipeline and corporate developments.
Pfizer’s (PFE) 1Q17 revenues reflected a decrease in revenues in both the Innovative Health and Essential Health segments.
Pfizer’s (PFE) revenues have been driven by growth in the sales of key products including Lyrica, Ibrance, Xalkori, and Xeljanz.
To better understand the factors affecting growth, let’s take a look at Pfizer’s performance in US markets and beyond in 1Q17.
Pfizer’s (PFE) portfolio includes medicines, vaccines, and consumer healthcare products. The company has segregated its operations into two businesses.
Pfizer (PFE) reported a 2% fall in its top line for 1Q17 as part of its latest earnings announcement on May 2, 2017.
Despite challenging dynamics in the hepatitis C (or HCV) segment, there are currently around 3 million HCV patients in the United States.
In its 1Q17 earnings conference conducted on April 29, 2017, Gilead Sciences (GILD) reiterated its full-year 2017 financial guidance.
On May 9, 2017, Dentsply Sirona (XRAY) is scheduled to announce its 1Q17 earnings. Wall Street analysts expect Dentsply Sirona’s 1Q17 revenue to be about $916.5 million.
Dentsply Sirona (XRAY) accounts for ~0.06% of the total holdings of the Vanguard Total Stock Market ETF (VTI). Dentsply Sirona is set to release its 1Q17 results on May 9, 2017.
Dentsply Sirona (XRAY) is set to release its 1Q17 results on May 9, 2017. Let’s take a look at Wall Street analysts’ recommendations and target prices for the company.
Analysts expect a rise of 0.6% in Pfizer’s (PFE) 1Q17 revenue to $13.1 billion following the increased sales of the Prevnar family and its Xalkori, Xeljanz, and legacy Hospira products.
Wall Street analysts expect Pfizer’s (PFE) top line to rise 0.6% to ~$13.1 billion in 1Q17. Its earnings per share are expected to be $0.67 in the quarter.
Headquartered in New York City, Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. Pfizer is set to release its 1Q17 earnings on May 2, 2017.
Wall Street analysts estimate that Merck’s top line will fall 0.7% to ~$9.3 billion in 1Q17. Also, analysts expect the company’s EPS to be $0.83 for 1Q17.
For 1Q17, analysts expect Merck and Co.’s (MRK) revenues to be ~$9.25 billion—nearly a 0.7% decrease compared to revenues of $9.31 billion in 1Q16.